Appili Therapeutics

11/24/2020

Health Canada clears Appili Therapeutics for New Phase 3 Clinical Trial to evaluate Avigan Tablets (favipiravir) in the prevention of COVID-19 in exposed individuals.
“Since Avigan comes in a pill form, it allows for easier administration than other approaches, which usually require injections or intravenous administration, and also enables patients to receive it early after exposure”, confirms Dr. Armand Balboni, CEO Appili Therapeutics.
Appili expects enrollment to begin early 2021.
Read more details below.

HALIFAX, Nova Scotia, November 24, 2020 – Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced initiation of its Phase 3 Post Exposure Prophylaxis for COVID-19 (PEPCO) study t...

11/19/2020

EVENT: : A Shot in the Arm for Canadian ? Hosted by Andrea Mandel-Campbell, featuring Appili Therapeutics Chief Financial Officer Kimberly Stephens, Bloom Burton & Co. Co-founder, Chairman and CEO Brian Bloom; National Bank Financial Equity Research Analyst Endri Leno, MSc MBA CFA and IMV Inc. Chief Executive Officer Frederic Ors.
The global race to develop a for COVID-19 has injected renewed life into the Canadian sector. How long will the boom last and how can companies and investors best take advantage of the opportunity? Click below to learn more and register. ,
Register here:

The global race to develop a vaccine for COVID-19 has injected renewed life into the Canadian biopharmaceutical sector. Longtime players and new upstarts are leveraging the capital markets to advance an array of new treatments at breakneck speeds. How long will the boom last and how can companies an...

11/13/2020

Messaging the COVID-19 vaccine: No shot is an antidote to community concerns

Getting more people interested in vaccination will depend on a pivot from a biomedical mode of discussing vaccination to a more civic conversation, urges one public health expert in this Q&A.

10/27/2020

Appili’s CEO Dr. Armand Balboni will share details about our drug development initiatives including the evaluating favipiravir for the treatment and prevention of COVID-19. Register for TSX’s first-ever Life Science Investor Day Virtual Conference: https://lnkd.in/e_kVQnz.

10/26/2020

Appili’s CEO Dr. Armand Balboni will be presenting at the TSX’s first-ever Life Science Investor Day Virtual Conference. The event will be held online on October 29, 2020. Dr. Balboni will share details about the drug development initiatives Appili Therapeutics Inc is working on, including the evaluating favipiravir for the treatment and prevention of COVID-19.
Register here:

10/19/2020

We salute the advances for dealing with COVID-19. This infection is impacting every corner of the globe, and finding effective treatments is the first step. Delivering it on a global scale is incredibly important as well. From novel advances to treat advanced disease, to antivirals that can be administered in the community setting, we need multiple approaches, and an arsenal of options, to tame this pandemic.

This is why the work we are doing to determine if is safe and effective, and who it may benefit the most, is so important, regardless of what we hear about vaccines, mABs, and other new technologies. Unlike other interventions being studied, favipiravir has a known safety profile and established manufacturing network.

We are proud to be part of the global effort to address the most significant public health issue of our generation.

Roche Pharma CEO Bill Anderson is excited about the prospects for REGN-COV2 but with the company and Regeneron possibly producing two million doses per year by the end of Q1 2021, meeting demand worldwide will be an impossible task.

10/15/2020

The US is focussed heavily on finding treatments of early infection and/or prevention of infection of COVID-19 according to Dr. Anothony Fauci. Appili is evaluating favipiravir as both early treatment and as a prophylactic drug for those potentially exposed to COVID-19, that can be this ‘bridge to a vaccine’. Successful antiviral treatment during the early stages of infection has been an effective strategy for other respiratory viruses such as influenza.

Monoclonal antibodies that stop the coronavirus from spreading in the body are among promising strategies for averting severe illness from Covid-19 before vaccines arrive, said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

10/07/2020

Appili Therapeutics CEO, Armand Balboni, will share his expert insights on what to expect with the second wave of the pandemic, giving special focus to the current diagnostics and vaccines in development.
COVID-19 webinar. Register to not miss important updates: https://bit.ly/34iCKEB.

09/16/2020

RSVP today and be a part of this engaging discussion with the CEO of Appili, Armand Balboni! https://bit.ly/2GWwD0E Thursday, September 17, 2020, 11...

05/11/2020

NEWS RELEASE - The FUJIFILM Toyama Chemical antiviral drug has shown early efficacy in multiple early trials against COVID19. This study is the first clinical program in the world designed to assess the use of favipiravir for outbreak control of COVID-19.

Learn more about our clinical trial: https://bit.ly/3fCtqAh

05/04/2020

NEWS RELEASE - Our CEO, Armand Balboni, will be a panelist for Maxim Group's Infectious Disease Virtual Conference where he will discuss our ATI-2307 drug program.

RSVP for the conference now: http://go.pardot.com/l/652223/2020-04-02/j1mqg

Our full release: https://bwnews.pr/2zc4X4g

04/23/2020

Our CEO, Armand Balboni, will be participating in Adelaide Capital Markets' Virtual COVID & Healthcare Mini Conference taking place today from 12pm-5pm EST.

Register now to find out how Canadian companies are working to fight the coronavirus pandemic: https://bit.ly/2KnqkBR